Literature DB >> 33449183

Diagnostic performance of loss of nigral hyperintensity on susceptibility-weighted imaging in parkinsonism: an updated meta-analysis.

Pyeong Hwa Kim1, Da Hyun Lee1, Chong Hyun Suh2, Minjae Kim1, Woo Hyun Shim1, Sang Joon Kim1.   

Abstract

OBJECTIVES: To evaluate diagnostic performance of loss of nigral hyperintensity on SWI in differentiating idiopathic Parkinson's disease (IPD) or primary parkinsonism (including IPD and Parkinson-plus syndrome) from healthy/disease controls.
METHODS: MEDLINE/PubMed and EMBASE databases were searched to identify original articles investigating the diagnostic performance of loss of nigral hyperintensity for differentiating IPD or primary parkinsonism from healthy/disease control, up to April 3, 2020. Pooled sensitivity and specificity were calculated using a bivariate random-effects model. The proportion of nondiagnostic scan, inter- and intrareader agreement, and the proportion of concordance between clinical laterality and imaging asymmetry were also pooled.
RESULTS: Nineteen articles covering 2125 patients (1097 with primary parkinsonism, 1028 healthy/disease controls) were included. For discrimination between IPD and healthy/disease controls, pooled sensitivity and specificity were 0.96 (95% CI, 0.91-0.98) and 0.95 (95% CI, 0.92-0.97). For discrimination between primary parkinsonism and healthy/disease controls, pooled sensitivity and specificity were 0.87 (95% CI, 0.75-0.94) and 0.93 (95% CI, 0.85-0.97). The pooled proportion of non-diagnostic scans on random-effects modeling was 4.2% (95% CI, 2.5-6.9%). The inter- and intrareader agreements were almost perfect, with the pooled coefficients being 0.84 (95% CI, 0.78-0.89) and 0.96 (95% CI, 0.89-0.99), respectively. The pooled proportion of concordant cases was 69.3% (95% CI, 58.4-78.4%).
CONCLUSIONS: Loss of nigral hyperintensity on SWI can differentiate IPD or primary parkinsonism from a healthy/disease control group with high accuracy. However, the proportion of non-diagnostic scans is not negligible and must be taken into account. KEY POINTS: • For discrimination between idiopathic Parkinson's disease and healthy/disease controls, pooled sensitivity and specificity of loss of nigral hyperintensity were 0.96 and 0.95. • For discrimination between primary parkinsonism and healthy/disease controls, pooled sensitivity and specificity of loss of nigral hyperintensity were 0.87 and 0.93. • The pooled proportion of non-diagnostic scans on random-effects modeling was 4.2%.
© 2021. European Society of Radiology.

Entities:  

Keywords:  Magnetic resonance imaging; Meta-analysis; Parkinson disease; Parkinsonian disorders; Substantia nigra

Mesh:

Year:  2021        PMID: 33449183     DOI: 10.1007/s00330-020-07627-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  43 in total

1.  How valid is the clinical diagnosis of Parkinson's disease in the community?

Authors:  K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

Review 2.  Magnetic resonance imaging of the substantia nigra in Parkinson's disease.

Authors:  Stéphane Lehéricy; Michael A Sharman; Clarisse Longo Dos Santos; Raphaël Paquin; Cecile Gallea
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

Review 3.  MDS clinical diagnostic criteria for Parkinson's disease.

Authors:  Ronald B Postuma; Daniela Berg; Matthew Stern; Werner Poewe; C Warren Olanow; Wolfgang Oertel; José Obeso; Kenneth Marek; Irene Litvan; Anthony E Lang; Glenda Halliday; Christopher G Goetz; Thomas Gasser; Bruno Dubois; Piu Chan; Bastiaan R Bloem; Charles H Adler; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

4.  Visualization of nigrosomes-1 in 3T MR susceptibility weighted imaging and its absence in diagnosing Parkinson's disease.

Authors:  P Gao; P-Y Zhou; G Li; G-B Zhang; P-Q Wang; J-Z Liu; F Xu; F Yang; X-X Wu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-12       Impact factor: 3.507

5.  Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease.

Authors:  Dae-Hyuk Kwon; Jong-Min Kim; Se-Hong Oh; Hye-Jin Jeong; Sung-Yeon Park; Eung-Seok Oh; Je-Geun Chi; Young-Bo Kim; Beom S Jeon; Zang-Hee Cho
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

6.  MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease.

Authors:  Mirco Cosottini; Daniela Frosini; Ilaria Pesaresi; Mauro Costagli; Laura Biagi; Roberto Ceravolo; Ubaldo Bonuccelli; Michela Tosetti
Journal:  Radiology       Date:  2014-02-26       Impact factor: 11.105

7.  Accuracy of diagnosis in patients with presumed Parkinson's disease.

Authors:  J Meara; B K Bhowmick; P Hobson
Journal:  Age Ageing       Date:  1999-03       Impact factor: 10.668

Review 8.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

9.  Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease.

Authors:  A J Hughes; S E Daniel; A J Lees
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

10.  The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T.

Authors:  Stefan T Schwarz; Mohammed Afzal; Paul S Morgan; Nin Bajaj; Penny A Gowland; Dorothee P Auer
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

View more
  1 in total

Review 1.  [Brain MRI-Based Artificial Intelligence Software in Patients with Neurodegenerative Diseases: Current Status].

Authors:  So Yeong Jeong; Chong Hyun Suh; Ho Young Park; Hwon Heo; Woo Hyun Shim; Sang Joon Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2022-05-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.